World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
54511
World Ranking
11954
National Ranking
6128

Overview

Jonathan E. Rosenberg is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research focuses mainly on medicine, with a strong emphasis on surgery and oncology, alongside contributions to pulmonary and respiratory medicine, molecular biology, and cancer research.

Their primary areas of study include several specialized topics within cancer treatment and research. These topics are:

  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Cancer Immunotherapy and Biomarkers
  • Esophageal Cancer Research and Treatment
  • Renal Cell Carcinoma Treatment
  • Epigenetics and DNA Methylation
  • Fibroblast Growth Factor Research

Jonathan E. Rosenberg has coauthored extensively with several collaborators, including:

  • Dean F. Bajorin
  • Gopa Iyer
  • Hikmat Al-Ahmadie
  • Bernard H. Bochner
  • Samuel A. Funt

Their research has been published frequently in notable scientific journals, with the most frequent venues being:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • European Urology
  • Clinical Cancer Research
  • Annals of Oncology

Significant recent publications authored or coauthored by Jonathan E. Rosenberg include:

  • EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma, 2020, Journal of Clinical Oncology
  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, 2021, New England Journal of Medicine
  • Genomic Characterization of Metastatic Patterns from Prospective Clinical Sequencing of 25,000 Patients, 2022, Cell
  • High Systemic and Tumor-Associated IL-8 Correlates with Reduced Clinical Benefit of PD-L1 Blockade, 2020, Nature Medicine
  • Adjuvant Atezolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial, 2021, The Lancet Oncology

Best Publications

  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

    Sanjeev Mariathasan;Shannon J. Turley;Dorothee Nickles;Alessandra Castiglioni

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Comprehensive molecular characterization of urothelial bladder carcinoma

    John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

    Sam S. Chang;Bernard H. Bochner;Roger Chou;Robert Dreicer

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    Thomas Powles;Jonathan E Rosenberg;Guru P Sonpavde;Yohann Loriot

  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim

  • Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Matthew D. Galsky;Noah M. Hahn;Jonathan Rosenberg;Guru Sonpavde

  • Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

    Eliezer M Van Allen;Kent W. Mouw;Philip Kim;Gopa Iyer

  • Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

    Jonathan E. Rosenberg;Jonathan E. Rosenberg;Peter H. O’Donnell;Arjun V. Balar;Bradley A. McGregor

  • Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Toni K. Choueiri;Ulka Vaishampayan;Jonathan E. Rosenberg;Theodore F. Logan

  • Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials

    Toni K. Choueiri;Fabio A.B. Schutz;Youjin Je;Jonathan E. Rosenberg

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

  • Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

    Joaquim Bellmunt;Toni K. Choueiri;Ronan Fougeray;Fabio A.B. Schutz

  • Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

    Min Yuen Teo;Kenneth Seier;Irina Ostrovnaya;Ashley M. Regazzi

  • Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.

    Jaegil Kim;Kent W Mouw;Kent W Mouw;Paz Polak;Lior Z Braunstein;Lior Z Braunstein

Frequent Co-Authors

Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Bernard H. Bochner
Bernard H. Bochner Memorial Sloan Kettering Cancer Center
Hikmat Al-Ahmadie
Hikmat Al-Ahmadie Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Thomas Powles
Thomas Powles Queen Mary University of London
Guido Dalbagni
Guido Dalbagni Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary pathways to a traditional MD can open doors to a wide range of rewarding healthcare careers. Many students consider online or hybrid degrees that offer flexibility and cost savings while still leading to important positions in the medical and health industry.

If you're interested in leadership or administration, earning an mha degree cost is a crucial factor to consider as you compare program options. For nurses aiming to advance their practice, some of the cheapest bsn to dnp programs provide a streamlined, affordable route from a bachelor's to a doctorate in nursing.

Those pursuing a career in pharmacy can benefit from enrolling in an online pharmd program, which combines flexibility with specialized training. Meanwhile, the demand for professionals skilled in managing clinical data is growing — earning a health information management degree online can set you on a path toward one of healthcare’s fastest-expanding fields.

Whether you’re seeking patient-facing roles, administration, or data-driven positions, exploring these online degree options can help you find an affordable and accessible path to a fulfilling career in healthcare.

Best Scientists Citing Jonathan E. Rosenberg

Trending Scientists

Recently Published Articles